可调节胃内球囊治疗肥胖:一项多中心、开放标签、随机临床试验
这项在美国7个中心开展的前瞻性随机试验将288名肥胖成人按2:1分配至可调节胃内球囊(aIGB)联合生活方式干预组或单纯生活方式干预对照组,疗程32周。32周时aIGB组平均总体重下降15.0%(95%CI 13.9-16.1),对照组为3.3%(2.0-4.6),p<0.0001;aIGB组临床应答率为92%。
要点
- 32周时aIGB组平均总体重下降15.0%(95%CI 13.9-16.1),对照组为3.3%(2.0-4.6),p<0.0001
- aIGB组171例(92%)达到临床应答(≥5%总体重下降)
- aIGB组31例(17%)因不耐受提前取出装置,7例(4%)发生装置相关严重不良事件,无死亡
核心结论
- aIGB联合生活方式调整可实现显著减重,并在装置取出后维持6个月。
- 球囊容积可调节性使个体化治疗成为可能,最大化了减重效果与耐受性。
研究设计与样本
- 前瞻性、多中心、开放标签、随机临床试验,在美国7个中心开展。
- 纳入22-65岁肥胖成人,按2:1随机分配至aIGB联合生活方式干预组(n=187,65%)或单纯生活方式干预对照组(n=101,35%),疗程32周。
- 球囊容积可增加以促进减重或减少以改善耐受性;采用多重插补意向性治疗人群分析;注册号ClinicalTrials.gov NCT02812160。
主要发现
- 32周时平均总体重下降:aIGB组15.0%(95%CI 13.9-16.1) vs 对照组3.3%(2.0-4.6),p<0.0001。
- aIGB组171例(92%)观察到临床应答。
- 145例(80%)aIGB患者因减重平台期或不耐受进行了容积调整;向上调容积额外促成平均5.2%(4.5-5.8)的总体重下降。
- 向下调容积使aIGB组21例(75%)患者完成全程治疗;31例(17%)因不耐受提前取出装置。
- aIGB队列未观察到微量营养素缺乏;7例(4%)发生装置相关严重不良事件,无死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity. METHODS: In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160. FINDINGS: Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5-5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths. INTERPRETATION: When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance. FUNDING: Spatz Medical.
引用
- Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021. PMID: 34793746. doi:10.1016/S0140-6736(21)02394-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。